Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance.
Rana R McKayLucia KwakJett P CrowdisJamie M SpergerShuang G ZhaoWanling XieLillian WernerRosina T LisZhenwei ZhangXiao X WeiJoshua M LangEliezer M Van AllenRupal S BhattEvan Y YuPeter S NelsonGlenn J BubleyR Bruce MontgomeryMary-Ellen TaplinPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Our results demonstrate that a large proportion of enzalutamide-treated patients have baseline and progression alterations in the AR pathway and tumor suppressor genes. We demonstrate an increased number of BRCA2 alterations post-enzalutamide, highlighting the importance of serial tumor sampling in CRPC.